Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Camurus stock

CAMX.ST
SE0007692850
A2ABG7

Price

0
Today +/-
-0
Today %
-0 %

Camurus stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Camurus stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Camurus stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Camurus stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Camurus's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Camurus Stock Price History

DateCamurus Price
1/28/20250 undefined
1/27/2025558.50 undefined
1/24/2025556.50 undefined
1/23/2025598.00 undefined
1/22/2025593.00 undefined
1/21/2025585.50 undefined
1/20/2025568.00 undefined
1/17/2025568.00 undefined
1/16/2025585.50 undefined
1/15/2025568.00 undefined
1/14/2025580.50 undefined
1/13/2025585.00 undefined
1/10/2025601.00 undefined
1/9/2025594.50 undefined
1/8/2025598.00 undefined
1/7/2025589.00 undefined
1/3/2025589.50 undefined
1/2/2025585.00 undefined
12/30/2024565.50 undefined

Camurus Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Camurus, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Camurus from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Camurus’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Camurus. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Camurus’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Camurus’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Camurus’s growth potential.

Camurus Revenue, EBIT and net profit per share

DateCamurus RevenueCamurus EBITCamurus Net Income
2030e14.43 B undefined0 undefined0 undefined
2029e11.94 B undefined9.03 B undefined0 undefined
2028e9.7 B undefined7.12 B undefined2.79 B undefined
2027e7.16 B undefined4.83 B undefined1.92 B undefined
2026e4.58 B undefined2.26 B undefined2.11 B undefined
2025e2.99 B undefined1.21 B undefined1.05 B undefined
2024e1.89 B undefined437.8 M undefined386.57 M undefined
20231.72 B undefined533.41 M undefined431.44 M undefined
2022956.34 M undefined65 M undefined55.55 M undefined
2021600.57 M undefined-112.36 M undefined-90.45 M undefined
2020336 M undefined-206.57 M undefined-167.27 M undefined
2019105.61 M undefined-360.09 M undefined-289.87 M undefined
201849.32 M undefined-287.78 M undefined-234.68 M undefined
201754.31 M undefined-243.52 M undefined-190.57 M undefined
2016113.74 M undefined-103.14 M undefined-80.99 M undefined
2015154.8 M undefined-29.81 M undefined-159.54 M undefined
2014208.21 M undefined62.32 M undefined48.35 M undefined

Camurus Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0.210.150.110.050.050.110.340.60.961.721.892.994.587.169.812.0614.58
--25.96-26.62-52.21-9.26114.29219.0579.1059.3379.509.9758.4553.0856.3936.9223.0320.93
99.52100.0098.2396.3085.7178.1089.5585.8389.2392.8984.4753.3134.8322.2716.2613.2210.93
0.210.150.110.050.040.080.30.520.851.590000000
0.05-0.16-0.08-0.19-0.23-0.29-0.17-0.090.060.430.351.031.921.922.7900
--431.25-49.69137.5023.1623.50-42.21-46.11-161.11683.64-19.49197.9885.69-0.0545.49--
27.5327.5340.7240.7241.3346.552.6854.4557.1757.50000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Camurus Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Camurus is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2014201520162017201820192020202120222023
                   
00.720.510.310.130.360.460.410.571.19
021.420.298.283.3536.1554.12136.67203.6288.43
05.73.863.299.65.235.4917.8921.7821.32
03.212.383.559.8333.09111.35107.2107.43100.96
03.14.474.749.746.515.745.9616.9923.52
00.750.550.330.170.440.670.680.921.62
06.69.769.910.938.3833.934.7334.8839.68
0000000000
0.41000000071.41
020.818.7416.6515.9837.3436.633.7123.622.75
0000000000
039.361.68115170.96256.64305.12334.15324.67219.91
0.4166.790.18141.55197.83332.36375.61402.6390.14283.75
00.820.640.480.360.771.041.081.311.91
                   
00.90.930.930.961.291.361.371.391.39
00.630.630.640.741.411.81.891.972.04
013.4-67.55-258.11-492.78-782.34-951-1,039.86-980.45-550.89
0000000000
0000000000
00.640.560.380.250.630.850.850.991.49
031.617.5615.0935.7817.3920.7152.8685.5599.28
04655.2372.6671.3688.2136.41125.56151.81213.69
098.22.573.195.267.4914.0627.934.7244.73
0000000000
000004.395.096.739.5710.89
0175.875.3690.93112.4117.47176.27213.05281.64368.59
0000022.9420.3918.9316.6413.61
8.08000000000
00000001.0212.5332.61
8.08000022.9420.3919.9429.1846.23
8.08175.875.3690.93112.4140.41196.66232.99310.82414.82
0.010.820.640.480.360.771.041.081.311.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Camurus provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Camurus's financial health and stability.

Assets

Camurus's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Camurus must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Camurus after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Camurus's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2014201520162017201820192020202120222023
62-204-102-243-287-360-205-11071525
00344011121213
0000000000
586-108368-53-45-58-23-31
111200090123998
001,000001,0001,0001,0001,0001,000
00900233610
69-5-207-203-274-404-238-143101606
-7-1-4-2-4-25-3-4-1-9
-94156-4-2-4-25-3-45-10
015800000070
0000000000
00000-3-4-7-14-9
25564411996573521065832
2556441199654347984328
00000000-75
0000000000
0716-207-194-180224103-50153624
62.23-7-212.36-205.21-278.85-430.27-242.16-148.3799.29597.69
0000000000

Camurus stock margins

The Camurus margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Camurus. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Camurus.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Camurus's sales revenue. A higher gross margin percentage indicates that the Camurus retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Camurus's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Camurus's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Camurus's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Camurus. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Camurus's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Camurus Margin History

Camurus Gross marginCamurus Profit marginCamurus EBIT marginCamurus Profit margin
2030e92.87 %0 %0 %
2029e92.87 %75.66 %0 %
2028e92.87 %73.39 %28.79 %
2027e92.87 %67.44 %26.81 %
2026e92.87 %49.4 %46.06 %
2025e92.87 %40.3 %35.03 %
2024e92.87 %23.2 %20.49 %
202392.87 %31.07 %25.13 %
202289.2 %6.8 %5.81 %
202185.79 %-18.71 %-15.06 %
202089.5 %-61.48 %-49.78 %
201977.95 %-340.98 %-274.48 %
201886.17 %-583.48 %-475.81 %
201797.5 %-448.41 %-350.91 %
201698.12 %-90.68 %-71.21 %
201599.85 %-19.25 %-103.06 %
201499.68 %29.93 %23.22 %

Camurus Stock Sales Revenue, EBIT, Earnings per Share

The Camurus earnings per share therefore indicates how much revenue Camurus has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Camurus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Camurus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Camurus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Camurus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Camurus Revenue, EBIT and net profit per share

DateCamurus Sales per ShareCamurus EBIT per shareCamurus Earnings per Share
2030e245.13 undefined0 undefined0 undefined
2029e202.7 undefined0 undefined0 undefined
2028e164.76 undefined0 undefined47.43 undefined
2027e121.57 undefined0 undefined32.6 undefined
2026e77.73 undefined0 undefined35.8 undefined
2025e50.78 undefined0 undefined17.79 undefined
2024e32.05 undefined0 undefined6.57 undefined
202329.86 undefined9.28 undefined7.5 undefined
202216.73 undefined1.14 undefined0.97 undefined
202111.03 undefined-2.06 undefined-1.66 undefined
20206.38 undefined-3.92 undefined-3.18 undefined
20192.27 undefined-7.74 undefined-6.23 undefined
20181.19 undefined-6.96 undefined-5.68 undefined
20171.33 undefined-5.98 undefined-4.68 undefined
20162.79 undefined-2.53 undefined-1.99 undefined
20155.62 undefined-1.08 undefined-5.79 undefined
20147.56 undefined2.26 undefined1.76 undefined

Camurus business model

Camurus AB is a Swedish biopharmaceutical company that specializes in the development of innovative medications for the treatment of serious diseases. The company was founded in 1991 by an interdisciplinary team of chemists, biologists, and drug developers and is headquartered in Lund, Sweden. Camurus AB specializes in the development of medications based on long-acting drug release technology. This technology allows medications to be administered in a very precise manner and over a longer period of time. This enables the benefits of a constant drug concentration in the blood to be utilized without requiring multiple doses per day. The core business of Camurus AB includes the development of medications for the treatment of pain, cancer, and addiction. The company works closely with clients, partners, and academic institutions to bring innovative medications to market that can have a significant impact on patients' lives. One of Camurus AB's key areas is pain therapy. The company has developed a novel technology that allows pain medications to be administered in the form of sprays and patches. This technology is based on the release of buprenorphine, a potent painkiller that previously could only be administered as repeated single doses or in the form of an implant due to its short half-life. The extended release allows for a sustained high concentration of the drug in the blood, without the need for the patient to take multiple single doses. Camurus AB is also active in oncology and has developed medications for the treatment of breast and prostate cancer that also utilize long-acting drug release. These medications help patients better tolerate the side effects of chemotherapy and improve their quality of life. Another important area for Camurus AB is addiction therapy. The company has developed a medication based on buprenorphine for the treatment of opioid dependence. This medication activates the body's own opioid receptors and reduces the cravings for further drugs. In recent years, Camurus AB has introduced several important products to the market and holds a wide portfolio of patents and protective rights. The company is committed to improving patient care and making global healthcare a better and more effective system. In conclusion, Camurus AB is an innovative biopharmaceutical company specializing in the development of medications for the treatment of pain, cancer, and addiction. The company is dedicated to improving global healthcare and works closely with clients, partners, and academic institutions to develop innovative, effective, and patient-oriented solutions. Camurus is one of the most popular companies on Eulerpool.com.

Camurus SWOT Analysis

Strengths

Camurus AB possesses a strong portfolio of innovative pharmaceutical products.

The company has a well-established reputation in the industry and is trusted by healthcare professionals.

Camurus AB has a robust and efficient manufacturing process, resulting in high-quality products.

The company's strong financial position allows for investments in research and development.

Weaknesses

Camurus AB may face challenges in terms of market competition and patent protection for its products.

The company's reliance on a limited number of key customers may pose a risk to its revenue stream.

Camurus AB's geographic presence is primarily focused on specific regions, limiting its market reach.

The company's dependence on external suppliers for raw materials may result in potential supply chain disruptions.

Opportunities

The growing demand for innovative pharmaceutical solutions presents opportunities for Camurus AB to expand its market share.

Strategic partnerships and collaborations with other pharmaceutical companies can enhance Camurus AB's product development capabilities.

Expansion into new geographic markets can provide Camurus AB with access to untapped customer segments.

The increasing focus on personalized medicine opens avenues for the development of tailored pharmaceutical products.

Threats

Regulatory changes and stringent approval processes may delay or hinder the launch of new products by Camurus AB.

The presence of generic competitors in the pharmaceutical market poses a threat to Camurus AB's market share and pricing strategy.

Rapid advancements in technology may require significant investments to keep up with industry trends.

Economic fluctuations and healthcare budget constraints can impact the purchasing power of Camurus AB's target customers.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Camurus Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Camurus historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Camurus shares outstanding

The number of shares was Camurus in 2024 — This indicates how many shares 57.497 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Camurus earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Camurus's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Camurus’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Camurus's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Camurus.

Camurus latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20241.48 2.16  (45.54 %)2024 Q3
6/30/20241.42 1.25  (-12.15 %)2024 Q2
3/31/20241.15 1.32  (15.2 %)2024 Q1
12/31/20230 -0.27  (0 %)2023 Q4
9/30/20230.83 1.5  (80.44 %)2023 Q3
6/30/20235.84 5.24  (-10.27 %)2023 Q2
3/31/20230.46 1.02  (122.22 %)2023 Q1
12/31/20220.3 0.23  (-23.13 %)2022 Q4
9/30/20220.14 0.63  (351.94 %)2022 Q3
6/30/2022-0.25 0.14  (156.02 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Camurus stock

Eulerpool World ESG Rating (EESG©)

90/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

72

Environment

Scope 1 - Direct Emissions
158.9
Scope 2 - Indirect emissions from purchased energy
11.6
Scope 3 - Indirect emissions within the value chain
385.6
Total CO₂ emissions
170.5
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees67
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Camurus shareholders

%
Name
Stocks
Change
Date
34.86870 % Sandberg (Per)20,530,692-1,345,0007/31/2024
4.43405 % Fj¿rde AP-Fonden2,610,766-40,0007/31/2024
3.36401 % Swedbank Robur Fonder AB1,980,728286,7707/31/2024
2.85362 % Avanza Bank Holding AB1,680,214-100,0117/31/2024
2.74287 % Tiberg (Fredrik)1,615,00007/31/2024
2.55723 % Handelsbanken Kapitalf¿rvaltning AB1,505,697369,0937/31/2024
1.60675 % The Vanguard Group, Inc.946,05321,9879/30/2024
1.22984 % Norges Bank Investment Management (NBIM)724,13123,7447/31/2024
1.17067 % AFA F¿rs¿kring AB689,29343,0007/31/2024
1.00115 % Devon Equity Management Ltd.589,475-2,0008/31/2024
1
2
3
4
5
...
10

Camurus Executives and Management Board

Mr. Fredrik Tiberg

(59)
Camurus President, Chief Executive Officer, Chief Scientific Officer, Director (since 2002)
Compensation 10.13 M

Mr. Per Wallstroem

(73)
Camurus Independent Chairman of the Board
Compensation 775,000

Ms. Hege Hellstroem

(58)
Camurus Independent Director
Compensation 350,000

Mr. Stefan Persson

(56)
Camurus Independent Director
Compensation 350,000

Mr. Ole Vahlgren

(60)
Camurus Independent Director
Compensation 350,000
1
2
3
4

Most common questions regarding Camurus

What values and corporate philosophy does Camurus represent?

Camurus AB represents a set of values and corporate philosophy rooted in innovation, collaboration, and patient-centricity. As a pharmaceutical company, Camurus AB is committed to developing and commercializing innovative drug delivery solutions to improve the lives of patients. They value scientific excellence, and their corporate philosophy emphasizes the importance of integrity, transparency, and ethical behavior in all aspects of their operations. Camurus AB strives to foster partnerships with healthcare professionals, patients, and stakeholders to deliver impactful treatments and make a positive difference in the field of medicine.

In which countries and regions is Camurus primarily present?

Camurus AB is primarily present in several countries and regions. The company has a strong presence in Europe, with a focus on Scandinavia. It operates in Sweden, where it is headquartered, as well as in Norway, Denmark, and Finland. Additionally, Camurus AB has expanded its operations to other European countries, including the United Kingdom, Germany, France, and Spain. It aims to further expand its global footprint through strategic partnerships and collaborations.

What significant milestones has the company Camurus achieved?

Some significant milestones achieved by Camurus AB include the approval and launch of their opioid dependence treatment medication, Buvidal® (buprenorphine and naloxone extended-release solution), in several countries, including the United States and European Union. The company has also received regulatory approvals for their product pipeline, such as the long-acting CAM2038 for the treatment of opioid addiction and pain, which further strengthens their position in the pharmaceutical market. Additionally, Camurus AB has formed strategic partnerships and collaborations with various pharmaceutical companies to commercialize their products globally. These milestones highlight the company's commitment to innovation and healthcare advancements in the treatment of addiction and pain management.

What is the history and background of the company Camurus?

Camurus AB is a Swedish pharmaceutical company specializing in developing and commercializing innovative drug delivery systems. Founded in 1991, Camurus has built a strong reputation for its proprietary drug delivery technologies, including the FluidCrystal® and the Buvidal® depot products. The company has successfully delivered numerous products to market, primarily in the areas of pain management and opioid dependence. With a focus on providing effective and patient-friendly medications, Camurus AB continues to expand its product portfolio and collaborate with global partners. This steadfast commitment to innovation has established Camurus AB as a leader in the pharmaceutical industry.

Who are the main competitors of Camurus in the market?

The main competitors of Camurus AB in the market are pharmaceutical companies such as Indivior PLC, Titan Pharmaceuticals Inc., and DURECT Corporation.

In which industries is Camurus primarily active?

Camurus AB is primarily active in the pharmaceutical industry.

What is the business model of Camurus?

The business model of Camurus AB is focused on the development and commercialization of innovative pharmaceutical products. Camurus specializes in long-acting medications, utilizing their proprietary FluidCrystal® technology to create advanced drug delivery systems. These systems enhance the efficacy, safety, and convenience of medication administration. The company primarily operates in the field of severe and chronic conditions, particularly within pain management and addiction treatment. By leveraging their expertise in drug formulation and delivery, Camurus aims to improve patient outcomes and quality of life.

What is the P/E ratio of Camurus 2025?

The P/E ratio cannot be calculated for Camurus at the moment.

What is the P/S ratio of Camurus 2025?

The P/S cannot be calculated for Camurus currently.

What is the Quality Investing of Camurus?

The Quality Investing for Camurus is 5/10.

What is the revenue of Camurus 2025?

The expected Camurus revenue is 2.99 B SEK.

How high is the profit of Camurus 2025?

The expected Camurus profit is 1.05 B SEK.

What is the business model of Camurus

Camurus AB is a Swedish biopharmaceutical company specializing in the development of innovative drugs. The company was founded in 1991 and is headquartered in Lund. Camurus has unique expertise in the formulation and manufacturing of long-acting drugs and is a leader in the development and commercialization of products for pain treatment, addiction disorders, and oncology. Camurus employs over 200 employees worldwide and pursues an international growth strategy with a focus on North America and Europe. The company collaborates closely with research-based pharmaceutical companies and academic institutions to help innovative drugs break through. Camurus is a strong and strategically focused company with a high degree of flexibility, dynamism, and innovation spirit. Camurus has two main divisions: the "Pharmaceuticals" business unit and the "Biovive" business unit. The "Pharmaceuticals" business unit focuses on the discovery and development of long-acting drugs in various therapeutic areas such as pain, addiction disorders, and oncology. The "Biovive" business unit is dedicated to the development of clinical dietary supplements and diagnostics to support oncology patient care. Camurus' flagship product is the opioid substitution preparation "Bunavail," which is used to treat opioid dependency. The uniqueness of Bunavail is that it is applied as a film on the inner cheek, ensuring a slow and continuous release of the active ingredient. This achieves better therapeutic effectiveness while reducing the potential for abuse. Camurus has other products in the pipeline, such as the pain product "CAM2038," which is intended for long-term therapy in chronic and acute pain. Camurus has successfully partnered with major pharmaceutical companies such as Braeburn Pharmaceuticals, ICM Pharma, and Meda to distribute its products worldwide. Camurus is also able to market its own products that are registered in the US, Europe, and other key markets. The company has international offices in the US and Europe and is continuously working to expand its network to increase global presence and growth. In summary, Camurus is an innovative biopharmaceutical company that focuses on the development of long-acting drugs in various therapeutic areas. Camurus' unique technology provides patients with better therapeutic effectiveness and safe drug handling, contributing to a better quality of life for patients. Camurus has a clear growth strategy to strengthen its position as a leading provider in the industry.

What is the Camurus dividend?

Camurus pays a dividend of 0 SEK distributed over payouts per year.

How often does Camurus pay dividends?

The dividend cannot currently be calculated for Camurus or the company does not pay out a dividend.

What is the Camurus ISIN?

The ISIN of Camurus is SE0007692850.

What is the Camurus WKN?

The WKN of Camurus is A2ABG7.

What is the Camurus ticker?

The ticker of Camurus is CAMX.ST.

How much dividend does Camurus pay?

Over the past 12 months, Camurus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Camurus is expected to pay a dividend of 0 SEK.

What is the dividend yield of Camurus?

The current dividend yield of Camurus is .

When does Camurus pay dividends?

Camurus pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Camurus?

Camurus paid dividends every year for the past 0 years.

What is the dividend of Camurus?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Camurus located?

Camurus is assigned to the 'Health' sector.

Wann musste ich die Aktien von Camurus kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Camurus from 1/28/2025 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 1/28/2025.

When did Camurus pay the last dividend?

The last dividend was paid out on 1/28/2025.

What was the dividend of Camurus in the year 2024?

In the year 2024, Camurus distributed 0 SEK as dividends.

In which currency does Camurus pay out the dividend?

The dividends of Camurus are distributed in SEK.

All fundamentals about Camurus

Our stock analysis for Camurus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Camurus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.